MedPacto hires global clinical expert Timothy R. Allen, Executive Vice President(EVP)
Mar 24, 2022
20 years of clinical medicine, research and leadership with the particular focus in the oncology serving the top 20’s including , BMS, GSK, Roche, and Sanofi.
Head of global clinical trials including Vactosertib colorectal cancer phase 3 clinical trial
[03-24, 2022] MedPacto, Inc, a genome-based drug discovery and clinical-stage biotechnology company, is accelerating its global clinical capabilities reinforcement by recruiting global clinical experts.
MedPacto announced on March 24th that it has recently appointed global clinical expert and former lead clinician at KaryoPharm, Dr. Timothy R. Allen as the EVP of Clinical Development at MedPacto Therapeutics, a U.S. corporation.
Dr. Allen is a clinical expert in the field of oncology with over 20 years of clinical experience serving global pharmaceutical companies such as Merck, BMS, GSK, Roche, AstraZeneca, and Sanofi. He most recently served as Vice President of Clinical Development at KaryoPharm (KPTI), a publicly traded global biopharmaceuticals with the focus on drug development in oncology.
Dr. Allen has a focused competence in research and development (R&D) in oncology, immuno-oncology, and the development of immune combination/formulation therapies for a variety of malignancies. He also has worked on development and their lifecycle development management of products in rare disease, CNS(MS), as well as cell/gene therapy.
Dr. Allen has held leadership positions in global clinical trials, including early phase trials as well as registrational trials, in the oncology field. Many of these trials tested immune-oncology drug candidates such as anti-CTLA-4, PD-1, and PD-L1, which are gaining market share in the cancer drug market.
In addition to Dr. Allen, MedPacto Therapeutics has recruited Ebla Ali Ibrahim as the Director of Regulatory Affairs (RA) and Cori Greutter as a Senior Clinical Project Manager. Ms. Ali Ibrahim worked for 11 years at FDA's Center for Drug Research (CDER) and Center for Biomedical Evaluation and Research (CBER), and has held many positions in global CROs and pharmaceutical companies. Ms. Greutter is a registered nurse with extensive clinical project management experience working at global biopharmaceutical companies and CROs.
In summary, the MedPacto Therapeutics team has considerable experience working with the US Food and Drug Administration (FDA), which is expected to add value to MedPacto's global clinical strategy.
Currently, MedPacto is conducting global clinical trials with 'Vactosertib', a TGF-β inhibitor, in collaboration with global pharmaceutical companies. A global phase 3 clinical trial testing 'Vactosertib + Keytruda' (colon cancer) is planned with MSD, and a US phase 2 study testing 'Vactosertib + Imfinzi' (bladder cancer) is in progress with AstraZeneca.
Dr. Allen will be in charge of the clinical strategy and global clinical trials of 'Vactosertib'. In addition, he will be in charge of global clinical development for next-generation candidates after Vactosertib.
MedPacto established a US corporation last year to accelerate global clinical trials and serve as a bridgehead to licensing-in/out pipelines to potential partners. In addition, it is expected that access to local medical institutions as well as the US FDA will increase in the future.
A representative from MedPacto said, "At this critical time of 'Vactosertib' development, we expect that the recruitment of global clinical experts will speed up the US studies as well as our global clinical trials."